沙格列汀联合二甲双胍治疗2型糖尿病的临床研究  

Study on the effect of saxagliptin combined with metformin on type 2 diabetes

作　　者：辛爽清[1] 米垚川[1] 孙媛媛[1] 王笑烨 于轶楠[1] 

机构地区：[1]辽宁省人民医院内分泌科,沈阳110016

出　　处：《实用药物与临床》2014年第10期1358-1360,共3页Practical Pharmacy and Clinical Remedies

摘　　要：目的观察2型糖尿病患者使用沙格列汀联合二甲双胍治疗后血糖的控制情况及血脂、体重指数的变化。方法选择40例2型糖尿病患者,随机分为2组。联合组20例,使用沙格列汀5 mg/d+二甲双胍2 000 mg/d;对照组20例,使用二甲双胍2 000 mg/d,治疗3个月。检测治疗前后空腹血糖(FPG)、餐后2 h血糖(PPG)、HbA1c、血脂、体重指数等,观察低血糖事件及其他不良反应。结果治疗后,联合组和对照组的空腹血糖、餐后血糖和糖化血红蛋白均显著下降,两组餐后血糖比较差异有统计学意义(P<0.05),低血糖发生率比较差异无统计学意义(P>0.05),且均未见严重不良反应。结论沙格列汀联合二甲双胍可改善2型糖尿病患者的血糖控制,无严重低血糖事件及其他不良反应。Objective To observe the effect of saxagliptin combined with metformin on blood glucose,lowdensity lipoproteinin and BMI of patients with type 2 diabetes. Methods Forty patients were randomly divided into two groups：combined treatment group（group A） and control group（group B）. Patients in group A were given metformin,2 000 mg /d,patients in group B were given the same dose of metformin with group A and saxagliptin 5 mg /d.After treatment of 3 months,the change of fasting glucose（FPG）,2 h postprandial glucose（PPG）,glycated hemoglobin（HbA1c）,cholesterol,body mass index and adverse reactions of the patients in the two groups were compared. Results The FPG,PPG,HbA1 c in group A decreased more significantly than that in group B（P〈0. 05）. There was no serious adverse reaction in the two groups（P〉0. 05）. Conclusion The blood glucose can be controlled in patients using saxagliptin and metformin with no serious hypoglycemia and other adverse reactions.

关 键 词：沙格列汀 二甲双胍 2型糖尿病 

分 类 号：R587.1[医药卫生—内分泌]